<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24633366</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial.</ArticleTitle><Pagination><StartPage>1366</StartPage><EndPage>1372</EndPage><MedlinePgn>1366-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/hv.28397</ELocationID><Abstract><AbstractText>The demonstration of batch-to-batch consistency to confirm the reliability of the manufacturing process has become a mandatory step in vaccine development. This is a post-hoc analysis aimed to provide more solid evidence on the immunogenicity and consistency of 3 consecutive batches of a novel inactivated enterovirus 71 (EV71) vaccine. In total 10&#x2009;245 healthy Chinese children aged 6-35 months had been recruited and randomized to receive one of 3 batches of EV71 vaccine or placebo according to a two-dose immunization schedule in a phase 3 clinical trial. Blood samples were taken just before and 28 days after vaccinations for serological tests of EV71 neutralizing antibody (NTAb) titer from the subjects. Among them, 7263 (70.9%) subjects with seronegative EV71 NTAb at baseline and the data of serological tests post-vaccination available were included for the analysis. The results showed that EV71 vaccine elicited high geometric mean titers (GMTs) of 407.0 U/mL (95% CI, 373.5-443.6) for batch 1, 468.1 U/mL (95% CI, 432.2-507.0) for batch 2, and 520.6 U/mL (95% CI, 481.2-563.3) for batch 3. The two-sided 95% confidence intervals (CIs) for the GMT ratios between each pair of vaccine batches were all within an interval of [0.67, 1.5]. Subjects who received EV71 vaccines demonstrated significant higher GMTs than those received placebos did (P&lt;0.001). In terms of incidence of both local and general adverse reactions, no differences were found among 3 vaccine batches and placebos. EV71 vaccine was highly immunogenic in children, and the 3 consecutive batches were well consistent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Juan</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>School of Public Health; Southeast University; Nanjing, Jiangsu Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fan-Yue</ForeName><Initials>FY</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Institute for Food and Drug Control; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing-Xin</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China; College of Pharmacy; Third Military Medical University &amp; National Engineering Research Center for Immunological Products; Chongqing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zheng-Lun</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>National Institute for Food and Drug Control; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-Tao</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Beijing Vigoo Biological Co., Ltd; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institute for Food and Drug Control; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qing-Hua</ForeName><Initials>QH</Initials><AffiliationInfo><Affiliation>Beijing Vigoo Biological Co., Ltd; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yuemei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Zi-Jun</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>School of Public Health; Nantong University; Nantong, Jiangsu Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Institute for Food and Drug Control; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hui-Jie</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Beijing Vigoo Biological Co., Ltd; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Feng-Cai</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiu-Ling</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Beijing Vigoo Biological Co., Ltd; Beijing, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">batch consistency</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24633366</ArticleId><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="doi">10.4161/hv.28397</ArticleId><ArticleId IdType="pii">28397</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. . Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778 - 90; http://dx.doi.org/10.1016/S1473-3099(10)70194-8; PMID: 20961813</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chiang PS, Luo ST, Huang ML, Liou GY, Tsao KC, Lin TY. . Incidence rates of enterovirus 71 infections in young children during a nationwide epidemic in Taiwan, 2008-09. PLoS Negl Trop Dis 2012; 6:e1476; http://dx.doi.org/10.1371/journal.pntd.0001476; PMID: 22348156</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001476</ArticleId><ArticleId IdType="pmc">PMC3279337</ArticleId><ArticleId IdType="pubmed">22348156</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et al. . . Establishing China&#x2019;s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29:9668 - 74; http://dx.doi.org/10.1016/j.vaccine.2011.10.018; PMID: 22015395</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health of the People&#x2019;s Republic of China. National notifiable diseases report. Available from: http://www.chinacdc.cn/tjsj/fdcrbbg</Citation></Reference><Reference><Citation>Chua KB, Kasri AR. . Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin 2011; 26:221 - 8; http://dx.doi.org/10.1007/s12250-011-3195-8; PMID: 21847753</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-011-3195-8</ArticleId><ArticleId IdType="pmc">PMC8222466</ArticleId><ArticleId IdType="pubmed">21847753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR, Taiwan Enterovirus Epidemic Working Group. . An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 1999; 341:929 - 35; http://dx.doi.org/10.1056/NEJM199909233411301; PMID: 10498487</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Feng Z, Yang Y, Self S, Gao Y, Longini IM, Wakefield J, Zhang J, Wang L, Chen X, et al. . . Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology 2011; 22:781 - 92; http://dx.doi.org/10.1097/EDE.0b013e318231d67a; PMID: 21968769</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e318231d67a</ArticleId><ArticleId IdType="pmc">PMC3246273</ArticleId><ArticleId IdType="pubmed">21968769</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ. . Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 2013; 9:1701 - 5; http://dx.doi.org/10.4161/hv.24949; PMID: 23744508</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. . . Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024 - 32; http://dx.doi.org/10.1016/S0140-6736(13)61049-1; PMID: 23726161</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Clinical considerations for evaluation of vaccines for prequalification. Points to consider for manufacturers of human vaccines. 2010 [cited 2013 September 12]. Available from:http://www.who.int/immunization_standards/vaccine_quality/clinical_considerations_oct10.pdf</Citation></Reference><Reference><Citation>Ahmed R, Gray D. . Immunological memory and protective immunity: understanding their relation. Science 1996; 272:54 - 60; http://dx.doi.org/10.1126/science.272.5258.54; PMID: 8600537</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.272.5258.54</ArticleId><ArticleId IdType="pubmed">8600537</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. Note for guidance on the clinical evaluation of vaccines. 2005 [cited 2013 September 12] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003875.pdf</Citation></Reference><Reference><Citation>Hendriksen C, Arciniega JL, Bruckner L, Chevalier M, Coppens E, Descamps J, Duch&#xea;ne M, Dusek DM, Halder M, Kreeftenberg H, et al. . . The consistency approach for the quality control of vaccines. Biologicals 2008; 36:73 - 7; http://dx.doi.org/10.1016/j.biologicals.2007.05.002; PMID: 17892948</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2007.05.002</ArticleId><ArticleId IdType="pubmed">17892948</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics JN. in Clinical Vaccine Trials. Springer, 2010.</Citation></Reference><Reference><Citation>Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, et al. . . Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008; 26:4057 - 61; http://dx.doi.org/10.1016/j.vaccine.2008.05.024; PMID: 18602726</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.05.024</ArticleId><ArticleId IdType="pmc">PMC2605420</ArticleId><ArticleId IdType="pubmed">18602726</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RL, Froeschle JE, Atmar RL, Matthews JS, Sanders R, Pardalos J, Moeller L, Chin JE, Famula M, Briggs DJ, et al. . . Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine 2001; 19:4635 - 43; http://dx.doi.org/10.1016/S0264-410X(01)00238-9; PMID: 11535311</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00238-9</ArticleId><ArticleId IdType="pubmed">11535311</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang WP, Chen JT, Wang X, Wang YL, Liu Y, Chen WY, Xu WG, Qiu YZ, Yin WD. . Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. Vaccine 2008; 26:2297 - 301; http://dx.doi.org/10.1016/j.vaccine.2007.11.008; PMID: 18395305</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.11.008</ArticleId><ArticleId IdType="pubmed">18395305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganju J, Izu A, Anemona A. . Sample size for equivalence trials: a case study from a vaccine lot consistency trial. Stat Med 2008; 27:3743 - 54; http://dx.doi.org/10.1002/sim.3273; PMID: 18416439</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3273</ArticleId><ArticleId IdType="pubmed">18416439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, Chang L, Liang ZL, Xia JL, Dai QG, Hu YL, et al. . . Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013; 20:1805 - 11; http://dx.doi.org/10.1128/CVI.00491-13; PMID: 24108780</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00491-13</ArticleId><ArticleId IdType="pmc">PMC3889509</ArticleId><ArticleId IdType="pubmed">24108780</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux-Roels G, Dobson S, Bernstein DI, Fowler S, Romanowski B, Leroux-Roels I, et al. . . Clinical evaluation to confirm the manufacturing consistency of three lots of an adjuvanted glycoprotein D genital herpes vaccine in healthy seronegative pre-teen and adolescent girls: A phase III multi-center double-blind randomized trial. Trials in Vaccinology 2013; 2:10 - 8; http://dx.doi.org/10.1016/j.trivac.2013.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trivac.2013.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, et al. . . A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013; 31:2471 - 6; http://dx.doi.org/10.1016/j.vaccine.2013.03.015; PMID: 23541623</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.015</ArticleId><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, et al. . . Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. J Infect Dis 2014; 209:46 - 55; http://dx.doi.org/10.1093/infdis/jit429; PMID: 23922377</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, et al. . . Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381:1037 - 45; http://dx.doi.org/10.1016/S0140-6736(12)61764-4; PMID: 23352749</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>ERADICATION P. Manual for the virological investigation of poliomyelitis. 1997 [cited 2013 September 12] Available from: http://whqlibdoc.who.int/Hq/1990/WHO_EPI_CDS_POLIO_90.1.pdf</Citation></Reference><Reference><Citation>State Food and Drug Administration. The standard guidelines for adverse reactions grading of vaccine clinical trials. 2005 [cited 2013 September 12] Available from: http://www.sda.gov.cn/WS01/CL0844/9350_5html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>